Meeting
2016 ASCO Annual Meeting
Phase 1, multicenter, open-label, dose-escalation, study of marizomib (MRZ) and bevacizumab (BEV) in WHO grade IV malignant glioma (G4 MG).
Authors
Daniela Annenelie Bota
UC Irvine Medical Center, Orange, CA
Daniela Annenelie Bota , Annick Desjardins , Warren P. Mason , Howard Alan Fine , Steven D. Reich , Mohit Trikha
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02330562
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2037)
DOI
10.1200/JCO.2016.34.15_suppl.2037
Abstract #
2037
Poster Bd #
225
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.
First Author: Annick Desjardins
Poster
2023 ASCO Annual Meeting
![FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose <i>e</i>scalation study for treatment of patients with select solid tumors.](https://d201v5jt9ylckg.cloudfront.net/299/15000/225830/225830_A945_poster_pv.jpg)
FRONTIER: FAPi radioligand open-label, phase 1 study to evaluate safety, tolerability and dosimetry of [Lu-177]-PNT6555—A dose escalation study for treatment of patients with select solid tumors.
First Author: Lisa Bodei
Poster
2023 ASCO Annual Meeting
A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.
First Author: Anthony W. Tolcher
First Author: R. Wendel Naumann